- Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
- Company announces Claudin 18.2 ISAC program with a poster detailing in vitro and in vivo experiments demonstrating potent anti-tumor activity
- Presentations will include trial-in-progress posters for ongoing clinical trials of BDC-1001, a HER2-targeting Boltbody™ ISAC, and BDC-3042, a novel Dectin-2 agonistic antibody
REDWOOD CITY, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will present four posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The conference is being held at the San Diego Convention Center in San Diego, Calif. and virtually from November 1-5, 2023.
"We are using our best-in-class ISAC platform and expertise in myeloid biology to teach the immune system to work with each patient's body to recognize and kill cancer," said Michael Alonso, PhD, scientific co-founder and Vice President, Immunology & Pharmacology of Bolt Biotherapeutics. "Our research team has made significant progress across our portfolio, highlighting our commitment to generate breakthroughs for patients. In addition to clinical-stage data that further validate our Boltbody™ ISAC technology, we are excited to show at SITC for the first time our preclinical work with a trastuzumab ISAC and pertuzumab and how the combination augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab."
Details about the poster presentations can be found below and on the SITC website. Additionally, a copy of each poster will be available on the Publications page of the Bolt Biotherapeutics website at the start of the poster session.
Title: The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Presenter: Cecelia I. Pearson, Ph.D.
Session Date and Time: Friday November 3, 2023, 9:00 a.m. – 7:00 p.m. PST
Location: San Diego Convention Center, Poster Hall
Abstract Number: 821
Title: Preclinical Characterization of a Novel Claudin 18.2 Targeting-ISAC with Robust Potency and Acceptable ...